As AI continues to disrupt the healthcare industry, more pharma companies are using algorithms to design drug molecules.
AI-driven pharma tech company Exscientia detailed how robotics and AI can be used to automate its entire end-to-end drug discovery workflow, at the ELRIG Drug Discovery 2024 meeting in London, UK, on 2 to 3 October.
Go deeper with GlobalData
Martin Redhead, associate vice president, Exscientia, detailed that the number of AI-designed molecules entering clinical trials has been increasing at an exponential rate since 2016, according to a publication by the Boston Consulting Group. Additionally, early data shows an 80% Phase I success rate for AI-designed molecules compared to a 15% industry average.
The Oxford-headquartered company’s automated system focuses on flexibility to run a variety of assays, rather than high-throughput screening (HTS). This allows the system to rapidly test and understand complex targets and mechanisms.
“Traditional assaying automation is focused on HTS, and that means a human will look after the stocks and take them out of freezers. A human will prepare them on the bench. A human will load up the robot, and the robot will do the same assay over and over and over at scale,” said Redhead.
He explained that automation has economically incentivised running more assays and generating increased data for AI, despite fewer experiments.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataExscientia recently unveiled a 26,000ft² robotic laboratory in Oxfordshire, UK. According to Redhead, the company has used AI to design four molecules in the last five years, all offering therapeutic classes with reduced human involvement.
However, Redhead emphasised that AI is not there to replace humans, but to increase productivity: “People often tell me that they are worried AI is going to take their job. What I think is exactly the opposite, it’s going to make you a lot more efficient. It is going to make you better at your job.”
Biotechs with AI-led drug pipelines appear to be attracting higher investment. In 2021, pharma giant Bristol-Myers Squibb signed a $1.2bn AI drug discovery deal with Exscientia to develop small molecules. Across healthcare, the AI market is expected to be worth $908.7bn by 2030 according to analysis by GlobalData.
GlobalData is the parent company of Pharmaceutical Technology.
